Hispanic Heritage Month and Psychedelics
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
Participant Safety in Psychedelic Therapy
All stakeholders at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) are committed to providing quality and comprehensive training and supervision …
Q4 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
On March 14, 2023, MAPS released a progress report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Read the Q4 2022 progress report here.
Big, if True: Did Australia Legalize MDMA and Psilocybin?
Distinctions in Australian MDMA and Psilocybin Policy The Therapeutic Goods Administration (TGA) in Australia recently announced a new policy allowing for the limited use of psychedelic-assisted therapies …
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
FDA Provides Additional Guidance for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
On January 19, 2023, the FDA advised MAPS that cannabis used in clinical trials is defined as a drug product, rather than a botanical raw material, for the purposes of microbiological testing acceptance …
MDMA Therapy Training Program Update: January 2023
The MDMA Therapy Training Program is not accepting applications at this time. Practitioners interested in learning more about the MDMA Therapy Training Program and future education opportunities can sign …
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Give the Gift of Healing: Donate to Psychedelic Therapy this December 2022
For the past 36 years, we’ve been working tirelessly towards making MDMA-assisted therapy a legal treatment option for PTSD. Over 12 million people suffer from PTSD in a given year, which means our psychedelic-assisted …
FDA Continues Clinical Hold for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
On December 16, 2022, the FDA advised MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued due to “insufficient information …
Policy and Advocacy Update: December 2022
There were many substantial legislative moments for psychedelics in 2022. States and municipalities across the country continue to seriously consider making changes to their laws governing psychedelic …
MDMA Therapy Training Program Update: December 2022
The MAPS PBC Training Team had a robust and fulfilling year launching newly designed education experiences, including a weeklong in-person retreat. The retreats were a learning journey for staff and trainees …